Figure 3.

Sensitivity analysis. (A) Cost-effectiveness (CE) relationship in terms of uncertainty of the monthly total costs per patient. (B) CE relationship in terms of the uncertainty of the metformin, glibenclamide, or acarbose monotherapy success probability (“success” being HbA_1c ≤7%). (C) CE relationship in terms of the uncertainty of the metformin with glibenclamide dual therapy success probability (“success” if HbA_1c ≤7%).

Notes: met + glib refers to glibenclamide addition after metformin monotherapy failure; glib + met refers to metformin addition after glibenclamide monotherapy failure.